Related Experiment Video
Updated: Mar 15, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
Published on: March 17, 2018
Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation
Ching Chang Cho1, Ruey-Hwang Chou2,3, Chin Yu1
1Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan.
Abstract:
The human S100A4 protein binds calcium, resulting in a change in its conformation to promote the interaction with its target protein. Human epidermal growth factor (EGF) is the target protein of S100A4 and a critical ligand of the receptor EGFR. The EGF/EGFR system promotes cell survival, differentiation, and growth by activating several signaling pathways. Amlexanox is an anti-inflammatory and anti-allergic drug that is used to treat recurrent aphthous ulcers. In the present study, we determined that amlexanox interacts with S100A4 using heteronuclear single quantum correlation titration. We elucidated the interactions of S100A4 with EGF and amlexanox using fluorescence and nuclear magnetic resonance spectroscopy. We generated two binary models (for the S100A4-EGF and S100A4-amlexanox complexes) and observed that amlexanox and EGF share a similar binding region in mS100A4. We also used a WST-1 assay to investigate the bioactivity of S100A4, EGF, and amlexanox, and found that amlexanox blocks the binding between S100A4 and EGF, and is therefore useful for the development of new anti-proliferation drugs.
Insights
The drug amlexanox binds to the S100A4 protein, blocking the interaction with epidermal growth factor (EGF). This finding suggests amlexanox
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- S100A4 protein binds calcium, altering its conformation to interact with target proteins.
- Human epidermal growth factor (EGF) is a target of S100A4 and a ligand for the EGF receptor (EGFR), regulating cell growth.
- Amlexanox is an anti-inflammatory drug used for aphthous ulcers.
Purpose of the Study:
- To investigate the interaction between amlexanox and S100A4.
- To elucidate the binding mechanisms of S100A4 with EGF and amlexanox.
- To assess the potential of amlexanox as an anti-proliferation drug by understanding its effect on the S100A4-EGF interaction.
Main Methods:
- Heteronuclear single quantum correlation (HSQC) titration to determine amlexanox-S100A4 interaction.
- Fluorescence and nuclear magnetic resonance (NMR) spectroscopy to study S100A4 interactions with EGF and amlexanox.
- WST-1 assay to evaluate the bioactivity of S100A4, EGF, and amlexanox.
Main Results:
- Amlexanox was found to interact with the human S100A4 protein.
- Both amlexanox and EGF bind to a similar region on S100A4.
- Amlexanox inhibits the binding between S100A4 and EGF.
Conclusions:
- Amlexanox shares a binding site with EGF on S100A4.
- Amlexanox effectively blocks the S100A4-EGF interaction.
- Amlexanox shows potential for developing novel anti-proliferation therapeutics.
Related Concept Videos
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Clinical Applications of Epidermal Stem Cells

